OKYO Pharma Receives $1.4M Funding
OKYO Pharma, a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP) and dry eye disease (DED), has...
Novel Factor XI Inhibitor Reduces Bleeding in Atrial Fibrillation
Anthos Therapeutics announced the publication of positive results from its AZALEA-TIMI 71 study in the •New England Journal of...
Discovery of New Immune Biomarkers in MS Patients Treated with Nasal Foralumab
Tiziana Life SciencesLife Sciences has discovered new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated...
Cullgen Begins Phase 1 Dosing of Pan-TRK Degrader for Pain
Cullgen Inc., a clinical-stage biopharmaceutical company, has initiated human trials for CG001419, a potential first-in-class, oral, pan-TRK protein degrader...
Certepetide Shows Promise in Metastatic Pancreatic Cancer Trial
Lisata Therapeutics announced preliminary data from Cohort A of its Phase 2 ASCEND trial evaluating certepetide, combined with standard...
Helius Pons Therapy Shows Positive Gait Improvement in MS Patients
Helius Medical Technologies announced positive results from their PoNSTEP study, demonstrating the long-term benefits of PoNS Therapy for gait...
Coherus’ Final Phase 2 Combination Data for Metastatic HCC at ASCO-GI 2025
Coherus BioSciences announced final data from its Phase 2 trial of casdozokitug (casdozo), an IL-27-targeting antibody, combined with atezolizumab...
Allurion Gets New US Patent for Next-Gen Weight Loss Device
Allurion Technologies received a patent for its enhanced, next-generation gastric balloon technology, specifically for its improved valve system. This...
Kiromic Biopharma Sees Tumor Volume Decrease in Two Deltacel-01 Patients
Kiromic BioPharma announced positive efficacy results from its Deltacel-01 Phase 1 clinical trial of Deltacel™, an allogeneic, off-the-shelf Gamma...
Nikang’s NKT2152 Dosed in First HCC Patient: Phase 1b/2 Trial Begins
NiKang Therapeutics has initiated a global Phase 1b/2 clinical trial evaluating NKT2152, an oral HIF2α inhibitor, in combination with...